3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
2
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Neuroepithelial
1
Glioma
1
Glioblastoma
1
Diffuse Intrinsic Pontine Glioma
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
39
Radiotherapy
18
Lomustine
12
Bevacizumab
11
Carmustine
8
Radiation
7
Procarbazine
4
Magnetic Resonance Spectroscopy
4
Surgical Procedures, Operative
3
pembrolizumab
2
depatuxizumab mafodotin
2
Tf-CRM107
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Drug Therapy
2
Dihematoporphyrin Ether
2
DNA Methylation
2
Carboplatin
2
ABT-414
2
trans-sodium crocetinate
1
tofacitinib
1
sargramostim
1
rindopepimut
1
niraparib
1
marizomib
1
enzastaurin
1
edotecarin
1
contrast agent BR1
1
cediranib
1
carmustine, poliferprosan 20 drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Glioblastoma
×
Valproic Acid
×
Clear all
NCT03243461
2022-06-06
HIT-HGG-2013
University of Göttingen
Phase 3
Unknown
167 enrolled